AbbVie prices $9.0B debt offering across 9 tranches (2028-2066) to fund acquisition

Filed August 6, 2026 · ~2 min read

Key Changes

• high

  AbbVie is offering $9.0 billion in notes across 9 tranches maturing 2028-2066, with rates from 4.500% (2028) to 6.100% (2066), plus floating-rate notes at SOFR + 0.420%. Net proceeds to the company are $9.9 billion after underwriting fees.

  The Offering verify on EDGAR →
• high

  Proceeds will fund a portion of the cash payment for a specified acquisition, transaction fees, and general corporate purposes including potential debt repayment. The offering is not conditioned on closing the acquisition.

  Use of Proceeds verify on EDGAR →
• high

  $7.0 billion of the notes (Mandatorily Redeemable Notes, maturities 2028-2038) must be redeemed at 101% of par plus accrued interest if the acquisition is terminated or AbbVie notifies the trustee it will not pursue it. The $2.0 billion in Long-Term Notes (2056, 2066) are not subject to this mandatory redemption.

  The Offering verify on EDGAR →